Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millennium Pharmaceuticals has won approval in the US for Velcade used in the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.
Subscribe to our email newsletter
Mantle cell lymphoma (MCL) is a relatively uncommon and aggressive form of non-Hodgkin’s lymphoma for which there was no standard of care in the relapsed or refractory setting.
“Mantle cell lymphoma is the most challenging lymphoma to treat because it is commonly resistant to chemotherapy in the relapsed setting,” said Andre Goy, chief of The Division of Lymphoma, The Cancer Center at Hackensack University Medical Center. “This approval offers new hope for patients with mantle cell lymphoma who have received at least one prior therapy.”
“In conjunction with our co-development partner, Johnson & Johnson Pharmaceutical R&D, Velcade is also being investigated in clinical studies in patients with newly diagnosed multiple myeloma and additional types of non-Hodgkin’s lymphoma.” said Deborah Dunsire, president and CEO, Millennium.
Earlier this year, Millennium and Johnson & Johnson Pharmaceutical R&D, initiated a phase III trial with Velcade in combination with rituximab in patients with relapsed or refractory follicular lymphoma, another subtype of non-Hodgkin’s lymphoma.